Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. Quiver AI Summary MIT and Recursion have released Boltz-2 ...

"Our partnership with Recursion underscores the transformative potential of real-world data in driving smarter clinical trials," said Andrew Kress, CEO of HealthVerity.

Recursion Pharmaceuticals announced results of a clinical trial for its lead drug candidate Tuesday that, while a success on paper, likely won’t satisfy many investors closely watching the AI ...

Catamorphisms, commonly known as folds, are fundamental recursive operations that collapse or aggregate complex data structures into simpler values by iteratively combining their elements with a given ...

Recursion plans to utilize this data to train causal AI models to accelerate drug discovery, design biomarkers, and develop patient stratification strategies across a range of disease states.

Recursion strengthened its tech stack through partnerships and collaborations with big players. Read why I will remain on the sidelines of RXRX stock.

Salt Lake City-based Recursion Pharmaceuticals Inc. RXRX is looking to tackle that problem with its artificial-intelligence models for drug discovery and 25-petabyte biological and chemical dataset.

Recursion uses a data-driven approach to drug discovery, launching four clinical trials in 2021 and planning a fifth in oncology. Click here to read more.

Recursion Pharmaceuticals just acquired a pair of AI-related biotechs. This could bolster its drug discovery capabilities and better help its clients. But the stock is high-risk and requires a ...